AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03377530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ways to prevent these infections.
Description: The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections.
Study NCT01173224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Study NCT05313204 — intervention group
Intervention type: OTHER
Intervention: Moderate-intensity cardiovascular exercise
Description: The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
Study NCT03797755 — intervention group
Intervention type: RADIATION
Intervention: palliative radiotherapy
Description: Radiotherapy for palliating symptoms in stage IV cancer patients
Study NCT00970281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Intramuscular Olanzapine
Description: Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
Study NCT00970281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
Study NCT06374030 — intervention group
Intervention type: PROCEDURE
Intervention: Endotracheal intubation
Description: All endotracheal intubations carried out in the emergency department of one of the participating hospitals in the time period 01-01-2019 - 31-12-2023
Study NCT04531228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE-HAIC plus lenvatinib
Description: chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
Study NCT03233620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Knee arthroplasty
Description: Effectiveness of knee arthroplasty surgery.
Study NCT03213119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.
Description: Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
Study NCT03213119 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.
Description: Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
Study NCT02756325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
Study NCT03413631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal mentalization intervention
Study NCT03413631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal obstetric treatment as usual
Study NCT03413631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal obstetric treatment as usual
Study NCT03012477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: chemotherapy
Study NCT03012477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Wee1 tyrosine kinase inhibitor
Study NCT01583777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days.
Study NCT00576381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
Study NCT02247479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Participants will receive 10 mg dose of lampalizumab administered intravitreally.
Study NCT02247479 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
Study NCT04326777 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ballon pulmonary angioplasty
Description: Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
Study NCT00564525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Medication taken for 4 weeks
Study NCT00564525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medication taken for 4 weeks
Study NCT03466190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium plate fixation
Description: Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
Study NCT03466190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Custom made PEEK plate fixation
Description: Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: 6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
Study NCT01443065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG102
Description: 10mg/kg over 60 mn every 2 weeks up to progression or toxicity
Study NCT03363074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole
Description: A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
Study NCT03363074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser
Description: A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
Study NCT03403764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness Intention
Study NCT00821392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Study NCT00821392 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Febuxostat
Study NCT00821392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Study NCT00718159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
Study NCT05653596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive intervention
Description: This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
Study NCT04989036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed
Study NCT04634448 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interval appendectomy
Description: interval appendectomy at 2 to 3 months after the initial non-operative treatment
Study NCT04634448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Follow-up MRI at 1 year
Description: follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
Study NCT04322071 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Qualitative interviews only
Study NCT03335371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399
Description: Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
Study NCT03335371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399
Description: Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
Study NCT03335371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Study NCT01055964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT01055964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT03361371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Battery operated nasal aspirator
Description: Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
Study NCT03361371 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Suction bulb
Description: Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
Study NCT03614377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Device interrogation
Description: All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
Study NCT01591707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISC+PRT Intervention
Description: Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
Study NCT02070744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661
Description: Tablet, oral use
Study NCT02070744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film coated tablet, oral use
Study NCT02070744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661
Description: Tablet, oral use
Study NCT02070744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Ivacaftor
Description: Film coated tablet, oral use
Study NCT01566409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350
Description: Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
Study NCT01566409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
Study NCT04089709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-arm Exercise
Description: Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
Study NCT01684358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sino-implant (II)
Description: Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
Study NCT01684358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sino-implant (II)
Description: Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
Study NCT01604044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropur 150 a day
Description: one subcutaneous injection a day
Study NCT01604044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f 150 plus Luveris 150
Description: one subcutaneous injection a day
Study NCT04282538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: 4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)
Study NCT04282538 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 4-week (5 days per week) sham rTMS
Study NCT04282538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: 4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)
Study NCT04282538 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 4-week (5 days per week) sham tDCS
Study NCT04282538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: 4-week (5 days per week) walking training
Study NCT04282538 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Walking training
Description: 4-week (5 days per week) walking training
Study NCT04282538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognition training
Description: 4-week (5 days per week) cognition training
Study NCT04282538 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognition training
Description: 4-week (5 days per week) cognition training
Study NCT04113343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Remimazolam via oral administration
Study NCT04113343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam via oral administration
Study NCT04113343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol
Study NCT04113343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Alcohol
Study NCT01144663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix™
Description: 4- or 3-dose intramuscular injection
Study NCT03548948 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Plant-based high non-heme iron diet
Description: A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet.
Study NCT01173224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
Study NCT02577146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal and bladder ultrasound with ureteral jet assessment
Description: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
Study NCT04600245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.
Description: One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
Study NCT00972673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator
Study NCT00972673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Inhaled steroid
Study NCT02690662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Description: recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
Study NCT03734835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin
Description: 1000 mg hesperidin as two capsules
Study NCT03734835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin and flaxseed
Description: 1000 mg hesperidin as two capsules and 30 grams flaxseed
Study NCT03734835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flaxseed
Description: 30 grams flaxseed
Study NCT03734835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study NCT03439202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypoxia
Description: Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.